Posted in | News | Nanoanalysis

Agilent Technologies Launches New Microarray Platform for Cytogenetic Research

Agilent Technologies Inc. (NYSE:A) today introduced the SurePrint G3 Human CGH+SNP microarray platform, an innovative system for simultaneous analysis of chromosomal copy number changes and copy-neutral aberrations.

The system allows researchers to study the genetic basis of developmental disorders as well as many cancers.

This is the only two-color CGH platform that can detect loss of heterozygosity/uniparental disomy (LOH/UPD) with 5- to 10-megabase resolution.

SurePrint G3 CGH+SNP microarrays

“Finally, we have an array that has optimal copy number detection, including the potential for exon-by-exon coverage, that also has SNPs to detect absence of heterozygosity [AOH] caused by UPD or consanguinity,” said Dr. Arthur Beaudet, chairman of the Department of Molecular and Human Genetics at Baylor College of Medicine.

“We’re excited to be adding SNP probes to our widely used CGH arrays, resulting in a powerful, highly efficient tool for detecting both copy number changes and copy-neutral LOH/UPD, delivering a more complete profile of genomic aberrations,” said Anniek De Witte, Agilent product manager, CGH Microarrays. “Resolution, accuracy and sensitivity continue at the same high levels that researchers have come to expect from our CGH offering.”

The Agilent SurePrint G3 CGH+SNP arrays are available in both catalog and custom designs, similar to our current array formats. Custom microarrays can be readily designed in eArray, Agilent’s free Web-based application, or eArray XD, the desktop version.

Both the catalog SurePrint CGH+SNP 4x180K and 2x400K microarrays measure approximately 60,000 SNPs, resulting in approximately 5- to 10-megabase resolution for LOH/UPD detection across the entire genome. The approximately 120,000 CGH probes on the catalog 4x180K arrays consist of the International Standards for Cytogenomic Arrays Consortium’s entire 8x60K version probe set and an additional 60,000 backbone probes. The approximately 300,000 CGH probes on the catalog 2x400K array are gene- and exon-biased, focusing coverage on the most important regions of the genome.

The SurePrint G3 CGH+SNP microarrays use the identical high-throughput workflow as the current CGH-only microarrays so they can be simply and efficiently incorporated into cytogenetic research. Agilent’s Genomic Workbench software compliments array analysis by employing novel algorithms to determine copy number changes using CGH probes, to measure allele-specific copy numbers of SNP probes, and to locate regions of LOH/UPD. The software enables concurrent analysis of CGH and SNP data alongside QC metrics for high-confidence data evaluation.

Source: http://www.agilent.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Agilent Technologies Inc.. (2019, February 13). Agilent Technologies Launches New Microarray Platform for Cytogenetic Research. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=19949.

  • MLA

    Agilent Technologies Inc.. "Agilent Technologies Launches New Microarray Platform for Cytogenetic Research". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=19949>.

  • Chicago

    Agilent Technologies Inc.. "Agilent Technologies Launches New Microarray Platform for Cytogenetic Research". AZoNano. https://www.azonano.com/news.aspx?newsID=19949. (accessed November 21, 2024).

  • Harvard

    Agilent Technologies Inc.. 2019. Agilent Technologies Launches New Microarray Platform for Cytogenetic Research. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=19949.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.